L
Luisa García-Buey
Researcher at Autonomous University of Madrid
Publications - 85
Citations - 3212
Luisa García-Buey is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Hepatitis C & Hepatitis C virus. The author has an hindex of 26, co-authored 77 publications receiving 3075 citations. Previous affiliations of Luisa García-Buey include Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial
José M. Mato,Javier Cámara,Javier Fernández de Paz,Llorenç Caballería,Susana Coll,Antonio Caballero,Luisa García-Buey,Joaquín Beltrán,Vicente Benita,Joan Caballería,Ricard Solà,Ricardo Moreno-Otero,Félix Barrao,Antonio Martín-Duce,Jose A Correa,Albert Parés,Elena Barrao,Inmaculada Garcı́a-Magaz,J. Puerta,Jorge Moreno,Gabrielle Boissard,Pablo Ortiz,Joan Rodés +22 more
TL;DR: It is indicated that long-term treatment with AdoMet may improve survival or delay liver transplantation in patients with alcoholic liver cirrhosis, especially in those with less advanced liver disease.
Journal ArticleDOI
Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis
TL;DR: HCV prevalence in patients with B-NHL is approximately 15%, higher than that reported not only in general population but also in Patients with other hematologic malignancies, suggesting a role of HCV in the etiology of B-nHL.
Journal ArticleDOI
Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis.
Roberto González-Amaro,Carmelo García-Monzón,Luisa García-Buey,Ricardo Moreno-Otero,J L Alonso,E Yagüe,J P Pivel,Manuel López-Cabrera,Elena Fernández-Ruiz,Francisco Sánchez-Madrid +9 more
TL;DR: It is demonstrated that viral infection induces, both in vivo and in vitro, TNF-alpha production in hepatocytes, and indicated that the HBV X protein may regulate the expression of this cytokine.
Journal ArticleDOI
Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis
TL;DR: Therapeutic strategies aimed at modulating insulin resistance, normalizing lipoprotein metabolism, and downregulating inflammatory mediators with probiotics have promising potential.
Journal ArticleDOI
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients
E. Gomez-Dominguez,Javier P. Gisbert,J.A. Moreno-Monteagudo,Luisa García-Buey,Ricardo Moreno-Otero +4 more
TL;DR: Atorvastatin is a new 3‐hydroxy‐3‐metylglutaryl coenzyme A reductase inhibitor that reduces lipid serum levels.